BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwartz PB, Stahl CC, Vande Walle KA, Pokrzywa CJ, Cherney Stafford LM, Aiken T, Barrett J, Acher AW, Leverson G, Ronnekleiv-Kelly S, Weber SM, Abbott DE. What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor? Ann Surg Oncol 2020;27:4920-8. [PMID: 32415351 DOI: 10.1245/s10434-020-08583-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 van der Zant FA, Kooijman BJL, Hentzen JEKR, Helfrich W, Ploeg EM, van Ginkel RJ, van Leeuwen BL, Been LB, Klaase JM, Hemmer PHJ, van der Hilst CS, Kruijff S. Impact of cumulative complications on 1-year treatment-related healthcare costs in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. BJS Open 2022;6:zrac109. [PMID: 36218348 DOI: 10.1093/bjsopen/zrac109] [Reference Citation Analysis]
2 Radomski SN, Florissi I, Khan H, Siddiqi A, Paneitz DC, Johnston FM, Greer JB. Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience. J Surg Oncol 2022. [PMID: 36081374 DOI: 10.1002/jso.27083] [Reference Citation Analysis]
3 Schwartz PB, Abbott DE. ASO Author Reflections: An Opportunity to Provide Cost-Conscious Care for Patients Undergoing CRS-HIPEC. Ann Surg Oncol 2022. [PMID: 35699815 DOI: 10.1245/s10434-022-12015-z] [Reference Citation Analysis]
4 Dellinger TH, Han ES. State of the Science: The role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol 2021;160:364-8. [PMID: 33419611 DOI: 10.1016/j.ygyno.2020.12.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]